Shares of ENDRA Life Sciences Inc (NASDAQ:NDRA) have been given a consensus broker rating score of 1.33 (Strong Buy) from the three analysts that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a buy rating and two have issued a strong buy rating on the company.
Brokers have set a twelve-month consensus price target of $5.50 for the company and are predicting that the company will post ($0.28) earnings per share for the current quarter, according to Zacks. Zacks has also given ENDRA Life Sciences an industry rank of 77 out of 256 based on the ratings given to related companies.
Several equities analysts have commented on the stock. ValuEngine upgraded shares of ENDRA Life Sciences from a “hold” rating to a “buy” rating in a research report on Thursday. Lake Street Capital assumed coverage on shares of ENDRA Life Sciences in a research report on Monday, May 20th. They set a “buy” rating for the company. HC Wainwright assumed coverage on shares of ENDRA Life Sciences in a research report on Monday, July 15th. They set a “buy” rating and a $6.00 price objective for the company. Finally, Dougherty & Co assumed coverage on shares of ENDRA Life Sciences in a research report on Thursday, June 13th. They set a “buy” rating for the company.
NDRA stock traded up $0.02 during trading on Friday, hitting $1.44. 55,970 shares of the company’s stock traded hands, compared to its average volume of 66,616. ENDRA Life Sciences has a 52 week low of $0.90 and a 52 week high of $5.75. The firm has a fifty day simple moving average of $1.59. The firm has a market capitalization of $9.94 million, a PE ratio of -0.69 and a beta of 1.43.
ENDRA Life Sciences (NASDAQ:NDRA) last released its quarterly earnings data on Tuesday, May 14th. The company reported ($0.37) EPS for the quarter. On average, sell-side analysts anticipate that ENDRA Life Sciences will post -1.03 earnings per share for the current year.
In other ENDRA Life Sciences news, insider Michael Milos Thornton acquired 30,000 shares of the stock in a transaction on Thursday, May 16th. The stock was acquired at an average price of $1.13 per share, for a total transaction of $33,900.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 11.40% of the stock is owned by company insiders.
Several institutional investors have recently added to or reduced their stakes in the company. Virtu Financial LLC lifted its holdings in shares of ENDRA Life Sciences by 109.2% in the 1st quarter. Virtu Financial LLC now owns 28,602 shares of the company’s stock worth $47,000 after acquiring an additional 14,930 shares during the last quarter. ICM Asset Management Inc. WA lifted its holdings in shares of ENDRA Life Sciences by 3.2% in the 2nd quarter. ICM Asset Management Inc. WA now owns 696,201 shares of the company’s stock worth $1,191,000 after acquiring an additional 21,875 shares during the last quarter. Finally, Geode Capital Management LLC bought a new stake in shares of ENDRA Life Sciences in the 4th quarter worth about $71,000. Hedge funds and other institutional investors own 16.88% of the company’s stock.
ENDRA Life Sciences Company Profile
ENDRA Life Sciences Inc develops medical imaging technology based on the thermos-acoustic effect that improves the sensitivity and specificity of clinical ultrasound. It offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding.
Further Reading: What is a growth and income fund?
Get a free copy of the Zacks research report on ENDRA Life Sciences (NDRA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ENDRA Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.